Head-to-head

CJC-1295 vs Semaglutide

A field-by-field comparison of CJC-1295 and Semaglutide drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. They belong to different categories — growth hormone and metabolic — so this page focuses on what each one actually does rather than which is "better".

CJC-1295 vs Semaglutide at a glance

Attribute	CJC-1295	Semaglutide
Category	Growth hormone	Metabolic
Evidence grade	Moderate	Strong
Also known as	Modified GRF 1-29, DAC:GRF	Ozempic, Wegovy
Chain	30 amino acid GHRH analogue	GLP-1 analogue, 94% homology to human GLP-1
Mechanism	Binds pituitary GHRH receptors to increase both the amplitude of GH pulses and total GH secretion. The DAC (drug affinity complex) version binds serum albumin, extending the half-life from minutes to about a week.	Mimics GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and act on hypothalamic appetite centres. Fatty-acid acylation extends its half-life to once-weekly dosing.
Reported benefits	Elevated GH and IGF-1 across the dosing window · Improved sleep depth reported by most users · Supports lean mass retention and fat oxidation	~15% mean body-weight reduction over 68 weeks in STEP-1 · Improved HbA1c and cardiovascular outcomes · Marked reduction in appetite and food noise
Reported side effects	Water retention · Tingling or numbness in hands · Head rush and flushing after injection · Elevated fasting glucose at higher doses	Nausea and vomiting · Constipation or diarrhoea · Gallbladder issues · Contraindicated with medullary thyroid carcinoma history
Half-life	~30 minutes without DAC; ~6–8 days with DAC	About 7 days
Administration	Subcutaneous injection, typically before bed on an empty stomach	Once-weekly subcutaneous injection (oral tablet also approved)
Dosing overview	100 mcg (no-DAC) 1–3× daily, or 1–2 mg weekly for the DAC version	Label titration from 0.25 mg weekly up to 2.4 mg over 16+ weeks
Storage	Refrigerate reconstituted product; protect from light and avoid shaking	Refrigerate 2–8 °C; in-use pens may be kept at room temperature per label
Legal status	Not FDA-approved. Prescribed off-label by some clinics; banned in sport.	FDA-approved and prescription-only.

Key differences between CJC-1295 and Semaglutide

Different categories, different goals

CJC-1295 is indexed under growth hormone, while Semaglutide sits under metabolic. They are not substitutes for one another: CJC-1295 is described as "A growth-hormone-releasing hormone analogue that raises the baseline of natural GH output rather than replacing it." and Semaglutide as "A long-acting GLP-1 receptor agonist with the strongest clinical weight-loss evidence of any peptide on the market."

Mechanism of action

CJC-1295: Binds pituitary GHRH receptors to increase both the amplitude of GH pulses and total GH secretion. The DAC (drug affinity complex) version binds serum albumin, extending the half-life from minutes to about a week. Semaglutide: Mimics GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and act on hypothalamic appetite centres. Fatty-acid acylation extends its half-life to once-weekly dosing.

Evidence quality is not equal

CJC-1295 carries a Moderate evidence grade and Semaglutide a Strong grade on this index. The grade describes the quality of published human data, not how well a compound works — Semaglutide has the better-documented record of the two, and claims made about CJC-1295 rest on thinner human evidence.

Half-life and dosing frequency

CJC-1295 is listed at ~30 minutes without dac; ~6–8 days with dac; Semaglutide at about 7 days. That difference is what drives the reported schedules: 100 mcg (no-DAC) 1–3× daily, or 1–2 mg weekly for the DAC version versus Label titration from 0.25 mg weekly up to 2.4 mg over 16+ weeks

Route of administration

CJC-1295 is administered by subcutaneous injection, typically before bed on an empty stomach. Semaglutide is administered by once-weekly subcutaneous injection (oral tablet also approved).

Legal and regulatory status differs

CJC-1295: Not FDA-approved. Prescribed off-label by some clinics; banned in sport. Semaglutide: FDA-approved and prescription-only. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.

Handling and storage

CJC-1295 is stored refrigerate reconstituted product; protect from light and avoid shaking. Semaglutide is stored refrigerate 2–8 °c; in-use pens may be kept at room temperature per label.

What CJC-1295 and Semaglutide have in common

On the attributes tracked in this database — category, evidence grade, mechanism, half-life, administration, dosing overview, storage and legal status — CJC-1295 and Semaglutide share no identical values. They are compared here because they come up together in the same searches, not because they overlap.

Each compound in brief

CJC-1295

Growth hormone · Moderate evidence

A growth-hormone-releasing hormone analogue that raises the baseline of natural GH output rather than replacing it.

Considerations: Usually paired with a GHRP such as Ipamorelin for a synergistic pulse · No-DAC (Mod GRF 1-29) suits pulsatile dosing; DAC suits steady elevation · GH elevation is not desirable for everyone — screen for cancer history

Semaglutide

Metabolic · Strong evidence

A long-acting GLP-1 receptor agonist with the strongest clinical weight-loss evidence of any peptide on the market.

Considerations: Muscle loss can account for a meaningful share of weight lost — resistance training and protein intake matter · GI side effects are dose-dependent; titrate slowly · Weight regain is common after stopping

CJC-1295 vs Semaglutide